STOCKS TELEGRAPH

Author: ST Staff

  • How poised is United Therapeutics Corporation’s (UTHR) stock for growing in 2021?

    How poised is United Therapeutics Corporation’s (UTHR) stock for growing in 2021?

    United Therapeutics Corporation (UTHR) stock closed Tuesday’s session at $199.30 and gained 0.36%. The stock volume traded was 0.41 million shares, slightly higher than the average daily volume of 0.4 million shares within the past 50 days. UTHR shares have risen by 102.85% over the last 12 months, and they have moved up by 3.99% in the past week. The UTHR stock has gained 18.61% over the past three months. The company is currently valued at $8.76 billion in the market and its outstanding shares stood at 44.50 million.

    United Therapeutics’ existing and developing product offerings

    United Therapeutics Corporation is a biotechnology company that focuses on the design, development and commercialization of therapeutic products. These treatments are to meet the unmet medical needs of patients that have chronic and life-threatening diseases in the US and around the world.

    The company already has a set of therapies that are commercially ready and are rolling out. These include:

    • Remodulin- helps get rid of symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients
    • Tyvaso- helps enhance the exercise ability in PAH patients (inhaled formula)
    • Orenitram- helps support the exercise ability in PAH patients (tablet dosage)
    • Unituxin- for treatment of high-risk neuroblastoma
    • Adcirca- enhances the exercise capacity in PAH patients (oral formula)

    UTHR stock has a subsidiary that is wholly owned by the name of Lung Biotechnology PBC. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotech company. The operations of this subsidiary are aimed at addressing the acute shortage of transplantable lungs nation-wide. There is also focus on a numerous technologies that either delays the need for organs that have shortages or increases their supply.

    Latest Tyvaso® approval by FDA for PAH patients

    In 2009, the United Therapy drug known as Tyvaso® was first approved for its treatment of pulmonary arterial hypertension (PAH) in order to improve the ability to exercise. On 1st April 2021, UTHR stock announced that the second round of approval of Tyvaso® has been approved to be used as a treprostinil-based inhalation solution that is used for specific pulmonary arterial hypertension patients which is associated with interstitial lung disease (ILD).

    Tyvaso® and Remodulin sale growth can rally UTHR stock for 2021

    Rolling out of Tyvaso® will be landmark news for the vulnerable patient population. Pulmonary Hypertension worsens the health of a patient affected with ILD especially if the patients have severe-ILD (PH affects 86% of patients with serious-ILD). The president of United Therapeutics states that advancement in the launch of this indication will be done with a sense of urgency as the company expands field-based teams by 40% to raise awareness among the ILD community.

    By the end of 2022, UTHR stock is expecting that uptake of Tyvaso® in the indication will double the number of patients on its therapy.

    The sales or Remodulin have slightly slumped since 2018 due to competition but the company is looking forward to launch the Remodulin delivery-device, Remunity pump this year. This device will function similarly to diabetic patients’ insulin pumps. Once this market of insulin pumps is penetrated along with commercialized launch of Tyvaso®, UTHR stock will see positive growth due to growth or at least stability in Remodulin sales.

  • Why Star Peak Energy Transition Corp (STPK) stock are falling in the current trading session?

    Why Star Peak Energy Transition Corp (STPK) stock are falling in the current trading session?

    Star Peak Energy Transition Corp. (STPK) shares were falling -8.73% to trade at $27.49 in the current market at the last check. STPK’s stock closed the previous session at $30.12. The STPK stock volume remained 1.3 million shares.

    What is the recent news on STPK stock?

    On 12th April 2021, STPK and Stem Inc. announced that they will host a fireside chat on that same day with IPO Edge at 2 pm EDT. The event will be broadcasted live and has also been announced by IPO Edge on their website. The event will feature the Chairman of STPK stock, Michael Morgan, and CEO of Stem, John Carrington. The moderator chosen for the event will be Editor-in-Chief of IPO Edge John Jannarone. The event’s agenda is to discuss merger/business combination and the session will last for 45 minutes along with a Q&A session with the audience

    Michael Morgan and John Carrington will talk on topics related to general discussions pertaining as to why shareholders regardless of how much they own, should vote for merger; what the main points of the merger; how shift of power grid to renewable energy will create opportunity for smart battery usage; how SPAC deals have evolved; how investors vote through their brokers.

    Both the companies are looking forward the Special Meeting to discuss the business combination and vote for it approval which will take place on 27th April 2021 at 11 am ET. Every shareholder owning STPK stock since 4th March (even if sold) should vote for the merger before 26th April’s deadline.

    About STPK

    Star Peak Energy Transition Corp. is a blank check company that has its headquarters in Delaware. The main objective of this company is effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

    The strongest aspect of the company is its management team which makes the core of the operational activities related to the acquisition. The executive team has broad, in-depth as well as extensive experience under their belt for investing specifically in the energy, energy sector, infrastructures, and renewable sectors. The company changed its name from Star Peak Energy Acquisition Corp to Star Peak Energy Transition.

    Background of the senior-most executives in Star Peak

    Michael Morgan is the Chairman of STPK while Eric Scheyer is the Chief Executive Officer. However, these are not the only executive seats that both senior-most executives are a part of. Michael Morgan is Chairman and CEO at Triangle Peak Partners LP and working under the title of director for Sunnova Energy international as well as the lead director of Kinder Morgan, Inc. Eric Scheyer is a partner at Magnetar and previously served as Head of the Magnetar Energy and Infrastructure Group right from the start when the company was founded.

    About Stem

    Stem is an energy storage solutions company that is uniquely differentiated in the energy market particularly by the fact that it is causing disruption in the energy market. It is doing so by combining Artificial Intelligence with a platform with energy storage solution services. The AI platform is known as Athena that serves as an analytical platform.  Stem provides full support to solar partners that are inclined towards adding storage to any scale of solar projects.

  • Why CBAK Energy Technology (CBAT) stock dropped in the current trading session

    CBAK Energy Technology Inc. (CBAT) stock slumped by -6.56% to trade at $4.42 in the current market at the time of writing. CBAT’s stock closed at $4.73 in the previous session. The CBAT stock volume traded at 1.28 million shares – lower than the average daily volume of 8.91 million shares in the past 100 days. The current market value of the stock is $438.05 million and the outstanding shares stood at 64.91 million.

    In the past week, CBAT stock moved down by -5.40%. Over the past three months, the stock has lost -37.76%, while over the past six months, it has added 27.49%. Furthermore, CBAT shares have risen by 1082.20% over the last 12 months.

    CBAK reports a positive outlook of the Full Year 2020 financial results

    Amidst the pandemic, CBAT stock grew and the company saw its total net revenue rise and its net losses fall. CBAK credits its robust business model and corporate strategy’s effectiveness which resulted in increasing financial capacity and capital mobilization for future development. The company released its financial report for 2020 on 12th April 2020.

    Financial Highlights of Fiscal Year 2020;

    • Total net revenues increased to US$37.6 million in FY 2020 compared to US$22.2 million in FY 2019 – a gain of 69.3%
    • Gross profit increased to US$2.7 million in FY 2020 compared to US$0.6 million in FY 2019
    • Net loss decreased to US$7.8 million in FY 2020 compared to US$10.9 million in FY 2019

    CBAK announces the addition of Fuel Cell development to its portfolio

    CBAK announced on 15th March 2021, that it has shown a keen expressed interest in the hydrogen fuel cell market by signing a memorandum of cooperation with a leading European Hydrogen energy group.

    The announcement does not specify if this is the actual name of the European Company or just a general description. However, CBAK does give details about the partner’s company operations and background.

    CBAK shows the consistent operational performance

    CBAK has been surging since the past year due to its growth potential in the EV market. CBAT stock maintained consistent operational activities during the EV market dip, which briefly propped up its stock value as it announced a new battery tech on Feb 19 which functions in ultra-low temperatures and known as 26650 lithium rechargeable batteries or simply Special 26650 battery.

    About CBAK Energy Technology

    CBAK Energy Technology, Inc. is an electrical equipment & parts company that deals with the production, manufacturing, and sale of electrification applications and solutions. The company has a diversified portfolio of electric products and solutions which include electric tools, electric cars, heavy electric vehicles, energy storage, uninterruptible power supply along with other powered applications. CBAT stock had recently entered the EV market and has been the first lithium battery manufacturer in China listed on the NASDAQ stock market. The company is currently a leading seller and manufacturer of the latest high-energy lithium battery.

  • Longeveron Inc. (LGVN) stock went up in the current trading session; here’s what recently happened

    Longeveron Inc. (LGVN) stock was rising 10.84% to trade at $7.87 in the current market at the time of writing.  LGVN’s stock closed at $6.92 in the previous session. The LGVN stock volume traded at a total of 14.95 million shares.

    Longeveron’s overall background and lead product development

    Longeveron is a clinical biotechnology company that specifically focuses on innovating and uniquely approaching the design, production, and testing of its therapies. The company differentiates its therapies by working on specific age-related and life threatening conditions.

    LGVN stock’s lead product is LOMECEL-BTM which is still in the developmental and trial phase. LOMECEL-BTMtherapy works as a cell-based product. It is a product derived through the culture-expanded medical signaling cells. These MSCs are then sourced from healthy and fit adult donors’ bone marrows. The concept behind the therapy for Longeveron’s product is that the cells that are associated with the function of tissue and organ repair, immune system function and maintenance, then it is possible to use them to procreate the same effects in therapies. The cell-based therapy would be used for the application of diseases and disorders that come with the aging process and other medical disorder.

    The recent news on LGVN stock

    On 13th April 2021, the LGVN stock announced that it has achieved primary safety endpoints of phase I clinical study of Lomecel-B cell for Alzheimer’s disease. The study has shown positive results which validate the secondary efficacy evaluation support potential benefit for Lomecel-B.

    The details in the press release of the Clinical Phase I trial indicated the “use of a randomized, placebo-controlled double-blind design which tested the single i.v of Lomecel-B 20 million cells and Lomecel-N 100 million cells or placebo”. The test studied the subjects for 52 weeks post the administration and fusion of the therapy. The trial was funded partly by an Alzheimer’s Association Part the Cloud Challenge on Neuroinflammationgrant.

    • Highlights of the key findings and preliminary data show that:
    • Lomecel-B’s trial test showed that it did not develop any treatment-related serious side-effects through the 1-year follow-up.
    • The average MME score that measures cognitive functioning, declined more slowly in low dosage of Lomecel-B and quicker in the placebo effect.
    • 26 weeks post the infusion time, patients in the low-dose Lomecel-B group showed significantly higher average score on the QOL-AD along with better ADCS-ADL measures as compared to the placebo group.

    Longeveron’s current and future prospects

    The investigative products of Longeveron are currently in phase 1 and 2 trials clinically and are being developed for the indication of: Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, ARDS, and HLHS.

    The company reported its financial outlook; the first quarter of 2021 saw an increased cash asset by $29.1 million through IPO funds. The cash position was $24.5 million as of 30th March 2021. The prediction by the company is that based on current operating plans the capital will be enough to drive them through the fourth quarter of 2022.

    The main current aim of LGVN stock is to advance all of its cell-based candidates including LOMECEL-BTM into the defining phase 3 trials along with completing the approval staging processes as well as commercialization phase. These successful developments in its operation boost the LGVN stock’s value.

  • NovoCure Limited (NVCR) stock is soaring today: Why is it so?

    NovoCure Limited (NVCR) announced an update related to its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer after which the NVCR price soared by 106.43% to reach $238.31 a share at the time of this writing. NVCR stock was down in the previous trading session and closed with a 0.16% drop. Let’s understand more about NovoCure stock.

    What’s happening?

    NovoCure Limited is an oncology company that develops, manufactures, and commercializes Optune to treat various types of solid tumors. An independent data monitoring committee recommended the continuation of the LUNAR trial after the analysis of the data of 210 patents accrued to the LUNAR trial through February 2021. Moreover, DMC recommended a 256 patients sample size with 12 months follow-up instead of 534 patients with 18 months follow-up as the former data would be sufficient for primary as well as secondary endpoints. The U.S. Food and Drug Administration has been notified of the recommendations of DMC by the NovoCure stock.

    The management is pleased with the DMC recommendations and believes that TTFields use with immune checkpoint inhibitors or docetaxel would create a significant impact in the treatment of non-small cell lung cancer. The management is planning to continue the development of TTFields for the treatment of various types of cancers.NovoCure’s CEO  Asaf Danziger considered the completion of the Lunar interim analysis as a major milestone for the NVCR and thanked the DMC members for their support. The management is looking forward to sharing the Final data of the Lunar trial as soon as possible.

    Financial View of NVCR stock:

    NovoCure stock will announce its first-quarter results of 2021 on Thursday, April 29, 2021.Wall Street analysts forecasted $136.54 million in sales for the first quarter of the company. NVCR stock generated sales of $101.83 million in the first quarter of 2020 which means that analysts have suggested a 34.1% growth rate of NVCR stock over the year. Analysts expect $582.87 million full-year sales of the current year and $669.26 million for the next fiscal year.

    Conclusion:

    Investors are responding to the NVCR stock news as NovoCure stock price has significantly risen today. The recent developments of NVCR point to the overall growth of the stock and analysts also forecasted 34% growth of NVCR stock over the year. The first-quarter results ahead would further clear the confusion of individuals. In a nutshell, NVCR can be a good bet for investors in the long run.

  • Why Aurora Mobile Limited (JG) stock is rising in Pre-Market today?

    Why Aurora Mobile Limited (JG) stock is rising in Pre-Market today?

    Aurora Mobile Limited (JG) announced the partnership agreement with Hangzhou Yivi Intelligent Technology Co., LTD after which the JG stock happened to be green as JG stock price saw a push of 3.72% to reach $3.62 a share in today’s pre-market at the time of this writing. JG stock saw a downtrend in the previous trading session and closed with a 12.53% drop. Let’s deep dive to explore more of it.

    What’s Happening?

    Aurora Mobile Limited is renowned as the big data solution provider in the Republic of China. The purpose of JG’s agreement with  Hangzhou Yivi Intelligent Technology Co., LTD (“Yivi”), a ride-hailing service platform, is to increase the technology strength as well as the expertise of both companies. Both of these companies will work together to explore more opportunities with the intention of advancement in smart travel and the development of highly efficient  AI-powered ride-hailing services.

    In connection with this agreement, Yivi will be able to enhance its intelligent operational capabilities as well as improve its operational efficiency via the Machine learning technology and AI-powered targeted push notification services of JG stock. Real-time data would be used with supply and demand along with shortening travel time in the smart travel to optimize the driver allocation, thus would enhance the user experience.

    Filing of Annual Report:

    Yesterday, Aurora stock did the announcement of filing its annual report of the fiscal year 2020 on Form 20-F with the securities and exchange commission.The hard copy of the annual report will be provided free of charge by the JG stock to its shareholders as well as ADS holders upon request.

    Previous Development of JG stock

    Back in the previous week, On April 08, 2021, Aurora Mobile signed an agreement with Beijing Koudai Fashion Technology Co., Ltd, also known as Weidian, in order to jointly work with the Beijing Koudai for the development of digital marketing, digital “new retail” and intelligent connected systems.JG stock will help Weidian through its advanced AI technology and analytical capabilities by providing the facility of integrated and end-to-end ecosystems that would serve brands, consumers, merchants, and developers.

    Conclusion

    The agreement news between JG stock and Yivi has captivated the attention of investors to JG stock. It seems that JG stock is leveraging its AI technology and analytical operational capabilities with time. Hence investors having long-term prospects need to keep an eye on JG stock.

  • RLX Technology Inc. (RLX) stock rises in the Pre-Market today: What’s going on?

    RLX Technology Inc. (RLX) stock rises in the Pre-Market today: What’s going on?

    Shares of RLX Technology Inc. (RLX) stock rose in the pre-market trading session today after facing a downtrend in the last trade. RLX stock price saw an uptrend of 2.80% to reach $8.80 a share as of this writing. There is no particular news or announcement linked with RLX to justify this rally. So here is what you need to know.

    What’s happening?

    RLX Technology along with its subsidiaries working on the research, development, manufacturing as well as distribution, and selling of e-vapor products in China. The current rally of RLX is not backed up by any news or earning report by the RLX stock. Also, there are no signs of analyst upgrades or social media hype to justify the bull. This is something unusual behavior which investors usually see in the stock market for many stocks.

    Financial View of RLX stock:

    We find no news about RLX stock in April but on March 26, 2021, RLX announced its fourth-quarter and full-year financial results of 2020 the summary of which is given below.

    In the fourth quarter ended on December 31, 2020, RLX generated RMB1,618.5 million net revenue which surpassed the net revenue of the third quarter by 44.5%. The gross margin was surged to 42.9% as compared to 39.1% in the third quarter.RLX recorded a net loss of RMB236.7 million in the fourth quarter while the net income was RMB7.8 million in the prior quarter.

    Net revenue for the full year 2020 increased significantly by 146.5% to RMB3,819.7 million as compared to RMB1,549.4 million in 2019. Gross margin reached 40.0% as compared to 37.5% in 2019 and the net loss was RMB128.1 million for the RLX stock in 2020. The estimated revenue for the fiscal year 2021 is more than RMB2.3 billion while more than RMB590 million is estimated for non-GAAP net income.

    RLX stock has beaten the analyst estimate according to the earnings report.RLX posted Q4 earnings of$0.05 per share while the consensus estimate was $0.04 per share.RLX reported a loss of RMB0.029 per share in the same tenure of last year.

    Conclusion:

    RLX stock is enjoying the bullish sentiment in the stock market despite the absence of any news related to it. Such behavior of the stock usually doesn’t last for long. Earnings report showed the growth of RLX stock over the year in terms of revenue. In a nutshell, a deep fundamental, as well as technical analysis, would be good practice for investors eyeing this stock.

  • Celcuity Inc. (CELC) stock soared in the after-market trading session; here’s what recently happened

    Celcuity Inc. (CELC) stock soared in the after-market trading session; here’s what recently happened

    Celcuity Inc. (CELC) shares went up by 4.87% to trade at $29.3 in after-market at the time of writing. CELC stock closed Monday’s session at $27.94 which is a 29.35% gain. The CELC stock volume traded around 4.86 million shares, which was higher than the average daily volume of 0.46 million shares within the past 50 days

    What is the recent news on Cecluity’s operational activities?

    On 12th April, Celcuity participated in the American Association for Cancer Research (AACR) Annual Meeting and there presented the outcomes of its studies which evaluated gedatolisib, inavolisib, and navitoclax in breast and ovarian patient tumors. Gedatolisib is a pan-P13K/mTOR inhibitor, inavolisib is a P13K-α inhibitor and navitoclax is a BCL inhibitor. Two e-posters were used by the company for the presentation of these studies and result.

    Results and characteristics of the study

    The posters presented the use of CELsignia test to characterize the role of RAS network nodes; CELsignia RAS Network Activity test that is used by the company identifies hyperactive RAS network signal done by the ovarian or breast cancer patients’ tumors. Furthermore, CELsignia also characterizes gedatolisib, inavolisib, navitoclax as well as RAS signaling role in the phospholipid-initiated signaling activity that is done through the lysophosphatidic acid (LPA) receptor family of GPCRs in the tumor cells and cell lines of ovarian and breast cancer patients.

    The results of these studies indicated that there is a potential advantage of not just inhibiting P13k-α signaling but inhibiting all Class 1 P13K isoforms as well as mTOR for treating P13K signaling tumors.

    Licensing agreement with pharma-giant Pfizer

    The CELC stock soared more than 50% on 9th April after it announced a licensing agreement with the world-renowned pharma-company Pfizer PFE. In the agreement, Celcuity paid $10 million to Pfizer in upfront payment as per the terms and Pfizer will receive up to $330 million in development and sales-based milestone from Celcuity along with royalties on future sales.

    Furthermore, Celcuity also announced a promise to present the preliminary data on the recent ongoing phase 1b  study evaluating gedatolisib in combination with Pfizer’s Ibrance as well as an endocrine therapy in Er+/HER2 – advanced or metastatic breast cancer patients. Phase II/III study of gedatolisib with the pfixer combo is expected to start in mid of 2022.

    Insight on Celcuity’s overall background

    Celcuity is a clinical stage biotechnology company that is specifically creating novel therapies and treatments in a unique and innovative approach towards cancer treatments. The company is differentiated based on its focus on creating integrated companion diagnostics and therapeutic strategy for cancer patients. The objective of this focus is to enhance and extend the lives of cancer patients.

    The companion diagnostics is able to identify the cancer driver in the patient and then the therapeutic efforts target the cancer driver molecularly. The proprietary diagnostic platform of CELC stock is known as CELsignia which has the tech-ability to analyze the live tumor cells that then identify new groups of cancer patients for whom targeted therapies are favorable. This diagnosis is furthered by CELsigniaCDx that supports the advancement new developing indications for the established targeted therapies.

    Based on this therapeutic strategy and integrated companion diagnostic, Celcuity is positioned in the cancer treatment and therapy market uniquely to treat the cancer driver in the most suited way possible for the patients.

  • Dragon Victory International Limited (LYL) stock soared in the after-hours trading session; here’s what is recently happening

    Dragon Victory International Limited (LYL) stock soared in the after-hours trading session; here’s what is recently happening

    Dragon Victory International Limited (LYL) shares have risen by 37.32% at the current price of $1.95 in the after-market, at the time of writing. LYL stock closed the Monday trading session at $1.42 which is a -7.79% loss. The stock volume traded was 1.86 million shares which is higher than the average daily volume of the past 50 days. LYL shares have risen by 42.00% over the last 12 months, and they have moved down by -10.13% in the past week. Over the past three months, the stock has lost -47.79%, while over the past six months, it has added 30.28%. Further, the company has a current market of $16.97 million and its outstanding shares stood at 11.42 million.

    Dragon Victory’s company insight

    Dragon Victory International Limited is a company that is based in China and is specifically engaged in the business of reward-based crowdfunding platform. The operation principally allows the provision of incubation and financial services to individuals and business institutes that are in need of funding. The funding is done through this crowdfunding platform known as 5etou – you can visit the website @ www.5etou.cn. This platform is designed to allow entrepreneurial activities of all sizes – small and medium sized companies, incubator ideas and start-ups – to raise funding from investors on the internet. LYL stock also provides these entrepreneurs and business entities business incubation services and guidance expertise which can again be done through utilization of their e-crowdfunding platform.

    Radio silence for more than 6 months

    Dragon Victory International Limited (LYL stock) has been non-active on the media platforms regarding its operational activities or any recent updates. Since the second quarter of 2020, there had been no active updates or progress related Press Release on LYL stock. LYL stock-wise, there had been low trade with its Year-To-Date performance being-39.32%. Furthermore, there had been exceptions in the trade performance within the past 5 months due to the army of redditors and retail-investors investing heavily in shorted stocks in December, January and then again recent hype on Twitter, Reddit, and Discord platform in February. This caused volatility in the stock price and the prices went to the moon in the previous-mentioned months.

    What caused the recent volatilities in the stock price?

    The recent climb of LYL stock price happened on 19th February when the price climbed to $3.78 after which hype on stock Twitter and Reddit around the short-squeeze play was spread around upon which investors acted. The same act happened in December when a Twitter account by the name @Mitch_Picks claimed to have interpreted the intention behind the LYL stock movement and the stock jumped more than 50% after which the account was blocked by Twitter.

    The LYL stock may see volatility again in the future due to Dragon Victory having a one-stop services auto repair shops that engage with auto-parts suppliers. The service had been upgraded by using blockchain for transactions so the involvement of cryptocurrency and its volatility can resonate with the stock itself.

  • Target Hospitality Corp (TH) soared in the recent trading session; here’s why

    Target Hospitality Corp (TH) soared in the recent trading session; here’s why

    Target Hospitality Corp. (TH) stock was rising 10.40% to trade at $3.45 in the current market at the last check. TH’s stock closed the previous session at $3.12. The TH stock volume remained 1.95 million shares, which was higher than the average daily volume of 1.26 million shares within the past 50 days. TH shares have risen by 82.75% over the last 12 months.

    TH stock announces Full Year and Fourth Quarter 2020 financial report

    TH stock had announced on 30th March 2021, its financial report for the Full year of 2020 and financial outlook for the year 2021.

    Here are the following highlights of the year ended 2020:

    • Revenue for the year ended 31st December 2020 was $225.1 million which is lower compared to $321.1 million for the full year 2019.
    • The net loss for the year ended 31st December 2020 was $27.5 million which is higher compared to $6.2 million for the full year 2019.
    • The net cash generated for the year ended 31st December 2020 through operational activities total $46.8 million and Discretionary Cash Flow for the same period is $45.9 million.
    • The liquidity of the company was equal to $84.0 million as of December 31, 2020.
    • The borrowings of the company have been reduced under its revolving credit facility by utilizing the $32 million from the Discretionary Cash Flow (DCF)
    • Adjusted EBTIDA for the year ended 31st December 2020 was $78.5 million compared to $159.2 million for the full year 2019.

    Highlights of the Fourth Quarter 2020

    • Revenue for Q4 2020 was $51.6 million compared to $76.1 million of Q4 2019.
    • Adjusted EBTIDA was $15.8 million Q4 2020, while $36 million for Q4 2019.
    • Q4 2020 experienced a net loss of $9.2 million compared to the net-income gain of $0.1 million for Q4 2019.
    • Average Daily Rate (ADR) for Q4 2020 was $69.92 which had decreased by $10.98 as compared to Q4 2019.
    • Overall utilization of TH’s services was 43% in Q4 2020 as compared to 76% in Q4 2019.

    Financial outlook of TH stock for 2021

    TH stock and company is expecting a modest return to normality of operational activities as the economy shows sign of improvements and vaccines roll out. Furthermore, the company had entered into a lease and services agreement with a national nonprofit organization on 29th March 2021, which is valued approximately at $118 million.

    The Company announced its 2021 financial outlook by saying that it is expected the Total revenue to be between $235 and $245 million. DCF is expected to be $55 and $60 million. Total capital spending is expected between $12 million and $17 million.

    Product offering by Target Hospital Corp

    Target Hospitality is known as the largest provider of differentiated rental accommodations and value-added hospitality services in the United States. These specialty services are vertically integrated. Target Hospitality has a complex of housing communities that are customized, built, and owned by the company for the purpose of selling as a cost-effective solution for end-users. Furthermore, these housing complexes also have a variety of hospitality solution provisions which include culinary, concierge, laundry, recreational activities as well as security services.

    TH stock’s clients primarily consist of public and energy sectors like investment grade oil and gas companies, government contractors, and energy infrastructure. Furthermore, it has a growing network of communities designed to maximize labor force, outcome, and satisfaction. The company operates and functions through three segments. These are the public sector as well as 26 communities in Bakken Basin and Permian Basin. The total rental accommodations it owns are 13,800 beds across 25 sites.